Immune Suppressant Stumbles for Acute Myocarditis in Early Data

(MedPage Today) -- AMSTERDAM -- Anti-inflammatory immunosuppressant anakinra (Kineret) held no survival benefit for acute myocarditis, the randomized phase IIb ARAMIS trial showed. The interleukin-1 receptor antagonist yielded a median 30 days...
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news